Pham Quang X, holding the titles of Chairman, Chief Executive Officer, and Interim Chief Financial Officer at Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), has recently completed the sale of company shares valued at $39,829. These transactions were facilitated through a Rule 10b5-1 trading arrangement, a pre-arranged plan adopted by Mr. Pham on September 25, 2025. The execution of these sales marks a specific divestment event within the company's leadership, structured under established regulatory frameworks for insider trading.
The initial tranche of sales occurred on June 22, 2026, when Mr. Pham divested 9,167 shares of common stock. The weighted average price for these transactions was recorded at $3.55 per share. Individual transaction prices within this batch ranged from a low of $3.51 to a high of $3.62. The following day, June 23, 2026, Mr. Pham executed a secondary sale of 2,277 additional shares. These subsequent transactions were settled at a weighted average price of $3.20 per share, with individual prices falling between $3.20 and $3.22. The total value of these two days of activity aligns with the reported $39,829 divestment figure.
Following these transactions, Mr. Pham's direct ownership position in Cadrenal Therapeutics stands at 117,145 shares. Furthermore, his indirect holdings include an additional 200,000 shares held through The PVBQ Living Trust. Mr. Pham serves as the trustee of this trust, with his child designated as the sole beneficiary. This structure maintains his economic interest in the company despite the recent sales activity.
The insider sales come at a time of significant market pressure for Cadrenal Therapeutics. The company's stock has experienced a substantial decline of 73% over the past year. As of the reporting period, the shares were trading at $2.98, a level near the 52-week low of $2.94. Despite this depreciation, analysis suggests the stock may be trading below its intrinsic value, with a calculated Fair Value of $3.27. This discrepancy indicates a potential valuation gap between current market pricing and fundamental assessments.
Amidst the market fluctuations, Cadrenal Therapeutics has reported operational milestones. For the fourth quarter ending December 31, 2025, the company reported a net loss of $3.0 million. This figure represents a reduction from the $4.2 million loss recorded in the same period of the previous year, suggesting a narrowing of quarterly losses. The company also completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). During this regulatory interaction, the FDA provided guidance for a pivotal Phase 3 trial of its drug candidate, CAD-1005, intended for the treatment of heparin-induced thrombocytopenia (HIT).
The upcoming Phase 3 trial is designed as a randomized, blinded, placebo-controlled study. It is expected to enroll approximately 120 patients globally. In parallel regulatory efforts, Cadrenal announced plans to submit a Rare Pediatric Disease Designation request to the FDA for tecarfarin, positioning it as a treatment for pediatric patients suffering from Kawasaki disease. Additionally, clinical data regarding CAD-1005 has been accepted for an oral presentation at the 34th Congress of the International Society on Thrombosis and Haemostasis in Paris. These activities underscore the company's continued progression through clinical trials and regulatory pathways.
The intersection of insider sales and clinical advancement presents a complex landscape for investors. While the executive's divestment reduces direct ownership, the pre-arranged nature of the trades under Rule 10b5-1 protocols suggests the activity was scheduled in advance. The company's focus remains on advancing its drug candidates through rigorous clinical phases, with the Phase 3 trial for CAD-1005 representing a critical next step in its development pipeline.